menu
    • menu
    [{"orgOrder":0,"company":"Verdiva Bio","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"VRB-101","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Verdiva Bio","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"Verdiva Bio \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Verdiva Bio \/ Forbion"}]

    Find Clinical Drug Pipeline Developments & Deals by Verdiva Bio

    Menu

    Verdiva Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Verdiva Bio

                            United Kingdom arrow
                            World Vape Show
                            Not Confirmed

                            Verdiva Bio

                            United Kingdom arrow
                            World Vape Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRB-101

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Forbion

                            Deal Size : $411.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Verdiva Bio Launches With $410M Series A to Develop Next-Gen Therapies

                            Details : The financing aims to advance the clinical development of the company pipeline product, which includes VRB-101 an oral, once-weekly GLP-1 receptor agonist for obesity.

                            Product Name : VRB-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : VRB-101

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Forbion

                            Deal Size : $411.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth